{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:24:05Z","timestamp":1787095445110,"version":"build-2736575974"},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Congenital factor V (FV) deficiency, affecting approximately 1 in 1 million individuals worldwide, remains among the rare bleeding disorders (RBDs) without a licensed factor-specific replacement therapy. While other RBDs have successfully transitioned from plasma-based treatment to approved factor concentrates\u2014exemplified by factor X deficiency's progression to US Food &amp; Drug Administration (FDA)-approved Coagadex and two FDA-approved concentrates for factor XIII deficiency\u2014FV deficiency treatment has remained unchanged for decades, relying solely on plasma and platelet transfusions. Two promising therapeutic candidates have emerged: a human plasma-derived FV concentrate demonstrating in vitro correction of severe deficiency, and an engineered activated FV (superFVa) showing potent hemostatic activity in preclinical models. This commentary outlines a pragmatic pathway to clinical trials, leveraging proven development strategies from other RBDs, existing registry infrastructure, and regulatory incentives for rare diseases. We propose phased trials combining pharmacodynamic endpoints with clinical outcomes, enabling feasible enrollment while generating decision-grade evidence. The time has come to extend modern therapeutic development to FV deficiency.<\/jats:p>","DOI":"10.1055\/a-2735-1659","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:37Z","timestamp":1761870457000},"page":"746-753","source":"Crossref","is-referenced-by-count":0,"title":["From Fresh Frozen Plasma to First-in-Human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials"],"prefix":"10.1055","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-9685","authenticated-orcid":false,"given":"Jeremy W.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee"},{"name":"Special Coagulation Laboratory, Vanderbilt Medical Laboratories, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheharyar","family":"Raza","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina A.","family":"Figueroa Villalba","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington"},{"name":"Department of Laboratory Medicine and Pathology, Seattle Children's Hospital, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Adkins","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine and Hemostasis, University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon C.","family":"Walker","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee"},{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett S.","family":"Booth","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deva","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee"},{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison P.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Washington Center for Bleeding Disorders, Seattle, Washington"},{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington"},{"name":"Division of Pediatric Hematology\/Oncology, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0029-1225760","article-title":"Factor V deficiency","volume":"35","author":"R Asselta","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1365-2516.2008.01785.x","article-title":"Factor V deficiency: a concise review","volume":"14","author":"J N Huang","year":"2008","journal-title":"Haemophilia"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MBC.0b013e3283424883","article-title":"Inherited and acquired factor V deficiency","volume":"22","author":"G Lippi","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2018-06-820738","article-title":"Treatment of rare factor deficiencies other than hemophilia","volume":"133","author":"M Menegatti","year":"2019","journal-title":"Blood"},{"issue":"13","key":"ref5","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","article-title":"Rare bleeding disorders: diagnosis and treatment","volume":"125","author":"R Palla","year":"2015","journal-title":"Blood"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/trf.18377","article-title":"Characterization and management of patients with hereditary factor X deficiency: a case series","volume":"65","author":"M Chitlur","year":"2025","journal-title":"Transfusion"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jth.12217","article-title":"The transition of prothrombin to thrombin","volume":"11","author":"S Krishnaswamy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1074\/jbc.270.9.4551","article-title":"The second kringle domain of prothrombin promotes factor Va-mediated prothrombin activation by prothrombinase","volume":"270","author":"K J Kotkow","year":"1995","journal-title":"J Biol Chem"},{"issue":"29","key":"ref13","doi-asserted-by":"crossref","first-page":"14884","DOI":"10.1016\/S0021-9258(18)68121-9","article-title":"Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection","volume":"263","author":"S Solymoss","year":"1988","journal-title":"J Biol Chem"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/trf.16179","article-title":"Factor V activity in apheresis platelets: implications for management of FV deficiency","volume":"61","author":"G K Gupta","year":"2021","journal-title":"Transfusion"},{"issue":"23","key":"ref15","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2014-07-589580","article-title":"Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency","volume":"125","author":"B A Bouchard","year":"2015","journal-title":"Blood"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2009-08-237719","article-title":"Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms","volume":"115","author":"C Duckers","year":"2010","journal-title":"Blood"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1182\/blood.V92.9.3035","article-title":"Secretable human platelet-derived factor V originates from the plasma pool","volume":"92","author":"R M Camire","year":"1998","journal-title":"Blood"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"F Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/jcm6040038","article-title":"Factor VII deficiency: clinical phenotype, genotype and therapy","volume":"6","author":"M Napolitano","year":"2017","journal-title":"J Clin Med"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2516.2004.00944.x","article-title":"The rare coagulation disorders\u2014review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"10","author":"P H Bolton-Maggs","year":"2004","journal-title":"Haemophilia"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/ejh.13941","article-title":"Management of rare inherited bleeding disorders: proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders","volume":"110","author":"M Trossaert","year":"2023","journal-title":"Eur J Haematol"},{"issue":"S 01","key":"ref23","first-page":"65S","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"S Pandey","year":"2012","journal-title":"Transfusion"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1537-2995.2011.03300.x","article-title":"Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing","volume":"52","author":"W P Sheffield","year":"2012","journal-title":"Transfusion"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12288-017-0879-8","article-title":"Coagulation factor activities changes over 5 days in thawed fresh frozen plasma stored at different initial storage temperatures","volume":"34","author":"S S Noordin","year":"2018","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"6260792","DOI":"10.1155\/2016\/6260792","article-title":"Stability of thawed apheresis fresh-frozen plasma stored for up to 120\u2009hours at 1\u00b0C to 6\u00b0C","volume":"2016","author":"W P Sheffield","year":"2016","journal-title":"J Blood Transfus"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/hae.12893","article-title":"Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency","volume":"22","author":"S K Austin","year":"2016","journal-title":"Haemophilia"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/hae.12954","article-title":"Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery","volume":"22","author":"M A Escobar","year":"2016","journal-title":"Haemophilia"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1111\/j.1365-2516.2012.02751.x","article-title":"Invasive procedures and minor surgery in factor VII deficiency","volume":"18","author":"G Mariani","year":"2012","journal-title":"Haemophilia"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3324\/haematol.2012.074039","article-title":"Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER)","volume":"98","author":"M Napolitano","year":"2013","journal-title":"Haematologica"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bjh.15055","article-title":"Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry","volume":"180","author":"M ND Di Minno","year":"2018","journal-title":"Br J Haematol"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/hae.13465","article-title":"\u201cIn vitro\u201d correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate","volume":"24","author":"C Bulato","year":"2018","journal-title":"Haemophilia"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1111\/hae.13636","article-title":"Thromboelastometry profiles after \u201cin vitro\u201d addition of a new plasma-derived factor V concentrate to whole blood from parahaemophilia patients","volume":"25","author":"C Bulato","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref34","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3324\/haematol.2020.253047","article-title":"Thrombin generation: a global coagulation procedure to investigate hypo- and hyper-coagulability","volume":"105","author":"A Tripodi","year":"2020","journal-title":"Haematologica"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0029-1225761","article-title":"Combined factor V and factor VIII deficiency","volume":"35","author":"M Spreafico","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0033-1349223","article-title":"Combined deficiency of coagulation factors V and VIII: an update","volume":"39","author":"C Zheng","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/bloodadvances.2021005257","article-title":"An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice","volume":"6","author":"B C Joseph","year":"2022","journal-title":"Blood Adv"},{"issue":"15","key":"ref38","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/bloodadvances.2020001699","article-title":"An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms","volume":"4","author":"A von Drygalski","year":"2020","journal-title":"Blood Adv"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1160\/th15-07-0525","article-title":"Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa","volume":"115","author":"V Bhat","year":"2016","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s11095-016-1895-3","article-title":"Safety, stability and pharmacokinetic properties of (super)factor Va, a novel engineered coagulation factor V for treatment of severe bleeding","volume":"33","author":"A J Gale","year":"2016","journal-title":"Pharm Res"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/hae.13847","article-title":"Potential of the Community Counts registry to characterize rare bleeding disorders","volume":"25","author":"S Gupta","year":"2019","journal-title":"Haemophilia"},{"issue":"06","key":"ref45","doi-asserted-by":"crossref","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and research and development intensity in the US, 2000-2018","volume":"7","author":"A Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"09","key":"ref46","doi-asserted-by":"crossref","first-page":"e2218623","DOI":"10.1001\/jamanetworkopen.2022.18623","article-title":"Association of research and development investments with treatment costs for new drugs approved from 2009 to 2018","volume":"5","author":"O J Wouters","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/jth.15287","article-title":"Recommendations for the measurement of thrombin generation: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"19","author":"M Ninivaggi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref51","doi-asserted-by":"crossref","first-page":"e0293632","DOI":"10.1371\/journal.pone.0293632","article-title":"Thrombin generation, bleeding and hemostasis in humans: protocol for a scoping review of the literature","volume":"18","author":"J R Shaw","year":"2023","journal-title":"PLoS One"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"P V Jenkins","year":"2020","journal-title":"Haemophilia"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2735-1659.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:32:53Z","timestamp":1787092373000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2735-1659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":42,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2735-1659","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,30]]},"published":{"date-parts":[[2025,10,30]]}}}